Cure8 research brief
A new stool-based host transcriptome method may offer noninvasive detection and monitoring for IBD and colorectal cancer, and the authors report a gene score that tracked endoscopic disease activity better than fecal calprotectin in their sample set.
Patients and clinicians interested in noninvasive IBD monitoring; researchers in stool biomarkers, transcriptomics, and colorectal cancer screening.
A medRxiv preprint reports a stool host-transcriptome test: sequencing human RNA recovered from stool samples to profile cells shed from the gut lining and immune cells.
The authors sequenced whole-transcriptome stool host RNA across samples including colorectal cancer (CRC), inflammatory bowel disease (IBD), precancerous lesions, and normals, and trained a classifier that separated CRC, IBD, and normal samples with high reported AUC (0.94–0.96).
Within IBD they describe a 15-gene neutrophil score measured in stool that the authors say tracked endoscopic activity more closely than fecal calprotectin in the same cohort.
The study is a preprint (not yet peer reviewed) reporting that stool host mRNA can reflect epithelial and immune cell contributions and may serve as a noninvasive biomarker for diagnosis and monitoring.
The test is described at the transcriptome level rather than as an already available clinical assay; implementation details, clinical validation, and regulatory status are not provided in the abstract.
If you follow IBD biomarkers, this suggests a potential new stool-based molecular approach that could complement or in future replace some uses of calprotectin or invasive endoscopy, but the findings require peer review, independent validation, and clinical assay development before they change care.
Preprint on medRxiv: not peer reviewed. Abstract-level extract only; full study details and independent validation are needed before clinical application.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
A simple blood-derived neutrophil activation marker (Neut-RI) correlated with clinical disease activity in ulcerative colitis and outperformed fecal calprotectin and CRP in this study, suggesting a potential low-cost,...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
Noninvasive fecal calprotectin levels tracked with endoscopic disease activity in children with colonic Crohn's disease, suggesting FC could help reduce repeat endoscopies and better monitor treatment response.
